These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 35489781)

  • 1. Role of Efficacy as a Determinant of Locomotor Activation by Mu Opioid Receptor Ligands in Female and Male Mice.
    Santos EJ; Banks ML; Negus SS
    J Pharmacol Exp Ther; 2022 Jul; 382(1):44-53. PubMed ID: 35489781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of Receptor Theory to the Design and Use of Fixed-Proportion Mu-Opioid Agonist and Antagonist Mixtures in Rhesus Monkeys.
    Cornelissen JC; Obeng S; Rice KC; Zhang Y; Negus SS; Banks ML
    J Pharmacol Exp Ther; 2018 Apr; 365(1):37-47. PubMed ID: 29330156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness comparisons of G-protein biased and unbiased mu opioid receptor ligands in warm water tail-withdrawal and drug discrimination in male and female rats.
    Schwienteck KL; Faunce KE; Rice KC; Obeng S; Zhang Y; Blough BE; Grim TW; Negus SS; Banks ML
    Neuropharmacology; 2019 May; 150():200-209. PubMed ID: 30660628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Manipulating Pharmacodynamic Efficacy with Agonist + Antagonist Mixtures: In Vitro and In Vivo Studies with Opioids and Cannabinoids.
    Selley DE; Banks ML; Diester CM; Jali AM; Legakis LP; Santos EJ; Negus SS
    J Pharmacol Exp Ther; 2021 Mar; 376(3):374-384. PubMed ID: 33443077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of delta opioid efficacy as a determinant of mu/delta opioid interactions in rhesus monkeys.
    Negus SS; Bear AE; Folk JE; Rice KC
    Eur J Pharmacol; 2009 Jan; 602(1):92-100. PubMed ID: 19027735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological Comparison of Mitragynine and 7-Hydroxymitragynine: In Vitro Affinity and Efficacy for
    Obeng S; Wilkerson JL; León F; Reeves ME; Restrepo LF; Gamez-Jimenez LR; Patel A; Pennington AE; Taylor VA; Ho NP; Braun T; Fortner JD; Crowley ML; Williamson MR; Pallares VLC; Mottinelli M; Lopera-Londoño C; McCurdy CR; McMahon LR; Hiranita T
    J Pharmacol Exp Ther; 2021 Mar; 376(3):410-427. PubMed ID: 33384303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of efficacy as a determinant of locomotor activation by mu-opioid receptor (MOR) ligands in female and male mice. II. Effects of novel MOR-selective phenylmorphans with high-to-low MOR efficacy.
    Santos EJ; Nassehi N; Bow EW; Chambers DR; Gutman ES; Jacobson AE; Lutz JA; Marsh SA; Rice KC; Sulima A; Selley DE; Negus SS
    Pharmacol Res Perspect; 2023 Aug; 11(4):e01111. PubMed ID: 37381112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic Characterization of Substituted Nitazenes at
    Kozell LB; Eshleman AJ; Wolfrum KM; Swanson TL; Bloom SH; Benware S; Schmachtenberg JL; Schutzer KA; Schutzer WE; Janowsky A; Abbas AI
    J Pharmacol Exp Ther; 2024 Apr; 389(2):219-228. PubMed ID: 38453524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fentanyl-related substances elicit antinociception and hyperlocomotion in mice via opioid receptors.
    Varshneya NB; Walentiny DM; Moisa LT; Walker TD; Akinfiresoye LR; Beardsley PM
    Pharmacol Biochem Behav; 2021 Sep; 208():173242. PubMed ID: 34302853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of agonist efficacy in exposure-induced enhancement of mu opioid reward in rats.
    Moerke MJ; Negus SS
    Neuropharmacology; 2019 Jun; 151():180-188. PubMed ID: 30880123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A low pKa ligand inhibits cancer-associated pain in mice by activating peripheral mu-opioid receptors.
    Baamonde A; Menéndez L; González-Rodríguez S; Lastra A; Seitz V; Stein C; Machelska H
    Sci Rep; 2020 Oct; 10(1):18599. PubMed ID: 33122720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective enhancement of fentanyl-induced antinociception by the delta agonist SNC162 but not by ketamine in rhesus monkeys: Further evidence supportive of delta agonists as candidate adjuncts to mu opioid analgesics.
    Banks ML; Folk JE; Rice KC; Negus SS
    Pharmacol Biochem Behav; 2010 Dec; 97(2):205-12. PubMed ID: 20678514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel fentanyl-based dual μ/δ-opioid agonists for the treatment of acute and chronic pain.
    Podolsky AT; Sandweiss A; Hu J; Bilsky EJ; Cain JP; Kumirov VK; Lee YS; Hruby VJ; Vardanyan RS; Vanderah TW
    Life Sci; 2013 Dec; 93(25-26):1010-6. PubMed ID: 24084045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding preference at the μ-opioid receptor underlies distinct pharmacology of cyclopropyl versus valeryl analogs of fentanyl.
    Xie B; Le Rouzic VP; Goldberg A; Tsai MM; Chen L; Zhang T; Sinha A; Pan YX; Baumann MH; Shi L
    Neuropharmacology; 2023 Apr; 227():109442. PubMed ID: 36731721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a novel "almost neutral" micro-opioid receptor antagonist in CHO cells expressing the cloned human mu-opioid receptor.
    Sally EJ; Xu H; Dersch CM; Hsin LW; Chang LT; Prisinzano TE; Simpson DS; Giuvelis D; Rice KC; Jacobson AE; Cheng K; Bilsky EJ; Rothman RB
    Synapse; 2010 Apr; 64(4):280-8. PubMed ID: 19953652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sex differences in the effectiveness of buprenorphine to decrease rates of responding in rhesus monkeys.
    Schwienteck KL; Negus SS; Banks ML
    Behav Pharmacol; 2019 Jun; 30(4):358-362. PubMed ID: 30212383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Affinity, potency, efficacy, selectivity, and molecular modeling of substituted fentanyls at opioid receptors.
    Eshleman AJ; Nagarajan S; Wolfrum KM; Reed JF; Nilsen A; Torralva R; Janowsky A
    Biochem Pharmacol; 2020 Dec; 182():114293. PubMed ID: 33091380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(indole-7-carboxamido)morphinan (NAN) as a Novel Opioid Receptor Modulator for Opioid Use Disorder Treatment.
    Obeng S; Jali A; Zheng Y; Wang H; Schwienteck KL; Chen C; Stevens DL; Akbarali HI; Dewey WL; Banks ML; Liu-Chen LY; Selley DE; Zhang Y
    ACS Chem Neurosci; 2019 May; 10(5):2518-2532. PubMed ID: 30758946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mu Opioids Induce Biased Signaling at the Full-Length Seven Transmembrane C-Terminal Splice Variants of the mu Opioid Receptor Gene, Oprm1.
    Narayan A; Hunkele A; Xu J; Bassoni DL; Pasternak GW; Pan YX
    Cell Mol Neurobiol; 2021 Jul; 41(5):1059-1074. PubMed ID: 33033993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Searching for Synthetic Opioid Rescue Agents: Identification of a Potent Opioid Agonist with Reduced Respiratory Depression.
    Vu LY; Luo D; Johnson K; Denehy ED; Songrady JC; Martin J; Trivedi R; Alsum AR; Shaykin JD; Chaudhary CL; Woloshin EJ; Kornberger L; Bhuiyan N; Parkin S; Jiang Q; Che T; Alilain W; Turner JR; Bardo MT; Prisinzano TE
    J Med Chem; 2024 Jun; 67(11):9173-9193. PubMed ID: 38810170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.